Comparative Pharmacology
Head-to-head clinical analysis: METRA versus METROLOTION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRA versus METROLOTION.
METRA vs METROLOTION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin primarily decreases hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), leading to reduced gluconeogenesis and increased peripheral glucose uptake.
Metrolotion is a formulation of metronidazole, a nitroimidazole antibiotic. Its exact mechanism is not fully understood, but it is believed to involve reduction of the nitro group in anaerobic bacteria and protozoa, leading to DNA disruption and cell death. It also has anti-inflammatory and immunosuppressive properties, possibly by inhibiting neutrophil chemotaxis and reactive oxygen species.
Adults: 20 mg orally once daily.
Topical metronidazole (Metrolotion) 1%: Apply a thin layer to affected areas once daily.
None Documented
None Documented
Clinical Note
moderatePhenmetrazine + Atomoxetine
"Phenmetrazine may increase the hypertensive activities of Atomoxetine."
Clinical Note
moderatePhenmetrazine + Iobenguane
"The therapeutic efficacy of Iobenguane can be decreased when used in combination with Phenmetrazine."
Clinical Note
moderatePhenmetrazine + Acebutolol
"The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Acebutolol."
Clinical Note
moderatePhenmetrazine + Isoxsuprine
Terminal elimination half-life: 3-7 hours (mean 4.5 hours). Increased to 8-15 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 18-24 hours; allows once-daily dosing.
Primarily renal: 70-80% unchanged drug via glomerular filtration and active tubular secretion; 15-20% biliary/fecal as metabolites.
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)
"The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Isoxsuprine."